Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $23.0052W HIGH $32.00
Volume
354.15 K
Value Traded
15.07 M
Short % Float
9.16%
-6.07%Week
-30.2%1 Month
+3.8%3 Month
-8.5%6 Month
-16.13%5 Year
-16.13%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.45 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
995.75 M
Total Shares
46.71 M
Float Shares
28.84 M
Insiders
38.27%
Institutions
64.79%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
COAG Catalyst Timeline
Dated clinical, regulatory and corporate events for Hemab Therapeutics Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hemab Therapeutics Holdings, Inc.
24Total events
4Upcoming
3Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 9
▲First Patient DosedHMB-003Trial
First participant dosed in Phase 1 trial of HMB-003
Heavy menstrual bleedingsource ↗
▲Topline ReadoutHMB-002Clinical Data
New clinical data on HMB-002 demonstrated 2.4-fold increase in VWF and Factor
▲Oral PresentationSutacimigPresentation
Phase 2 LTE data for sutacimig in GT presented at ISTH 2026
Glanzmann thrombastheniasource ↗
▲FDA Feedback ReceivedSutacimigFDA Meeting
FDA endorsed clinical data package for sutacimig Phase 3 dose
Glanzmann thrombastheniasource ↗
▲Oral PresentationHMB-002Presentation
Clinical data for HMB-002 in VWD presented at ISTH 2026
Von Willebrand diseasesource ↗
●Oral PresentationHMB-003Presentation
HMB-003 program announced at ISTH 2026
Multiple (heavy menstrual bleeding, HHT, peri-operative bleeding)source ↗
◆Trial InitiationSutacimigTrial
Phase 3 trial initiation for sutacimig in GT planned
Glanzmann thrombastheniasource ↗
Past FDA Catalysts and PDUFA Decisions
How COAG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-14 | Sutacimig (HMB-001) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$67M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 51%
Micro Cap(rank 336 of 658)
Percentile Rank
Hemab Therapeutics Holdings, Inc. faces pipeline headwinds (36/100), with $168M risk-adjusted pipeline value, led by HMB-002 in Von Willebrand Disease (VWD) (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HMB-002 Small moleculeNCT06754852 | Von Willebrand Disease (VWD) | Phase 1 | RECRUITING | 108 | Jul 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every COAG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| sutacimig BreakthroughFast TrackOrphan | Glanzmann thrombasthenia and Factor VII deficiency | Phase 2 | 2026-07-14 | 92% of participants who had bled during the run-in experienced reductions in treated bleed rates on sutacimig; the mean high intensity annualized treated bleed event rate was reduced by 62% over the treatment and extension period; the mean ATBR was reduced over the treatment and extension period; in the low dose weekly regimen cohort, the mean ATBR was reduced by approximately 84%Read More | Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 CongressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.10% Owner | Buy | 61,523 6,444,637 held | $24.98 | 06/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COAG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.2 % | 1.65 M | 45.00 K |
COAG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How COAG ranks across every disease it competes in
Competitive Position is a premium feature
See how COAG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCOAG News
COAGHemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Hemab Therapeutics has appointed Keli Walbert to its Board of Directors, effective September 24, 2026. Walbert, who brings over 20 years of commercial leadership experience, will join the Audit Committee and replace Akshay Vaishnaw. Her background in launching therapies for various diseases is expected to strengthen Hemab's efforts in developing treatments for bleeding disorders.
Read more →COAGHemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Hemab Therapeutics has initiated a Phase 1 clinical trial for HMB-003, a novel therapy aimed at managing heavy menstrual bleeding. This investigational treatment, designed to inhibit plasmin and stabilize blood clots, has shown promising results in preclinical studies. The trial aims to evaluate its safety and pharmacokinetics, with results expected by mid-2027.
Read more →COAGHemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Hemab Therapeutics reported its second quarter 2026 financial results, highlighting key scientific presentations at the ISTH 2026 Congress in Paris. The company showcased new clinical data for HMB-002, which demonstrated a notable 2.4-fold increase in Von Willebrand Factor (VWF). This progress reflects Hemab's commitment to advancing its therapeutic programs.
Read more →COAG▲ +9.6%on this news· ran to +25% by day 3
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Hemab Therapeutics presented promising clinical and preclinical data for sutacimig at the ISTH 2026 Congress, showing significant bleed reduction in patients with Glanzmann thrombasthenia and Factor VII deficiency. The Phase 2 long-term extension data indicated a manageable safety profile and FDA agreement on advancing to Phase 3 trials. Additionally, preclinical findings suggest sutacimig's broad applicability in treating bleeding disorders.
Read more →COAGHemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
Hemab Therapeutics presented promising clinical data for HMB-002 in treating Von Willebrand Disease and introduced HMB-003 for heavy menstrual bleeding at the ISTH 2026 Congress. HMB-002 demonstrated significant increases in Von Willebrand Factor and Factor VIII, supporting its potential for monthly dosing. HMB-003 is designed as a non-hormonal antifibrinolytic to address heavy menstrual bleeding, aiming to provide effective treatment options for women.
Read more →COAG▲ +16.8%on this news· ran to +33% by day 1
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
Hemab Therapeutics announced significant advancements in its blood coagulation programs, including promising first-in-human data for HMB-002 in Von Willebrand disease and the introduction of HMB-003, a new peptide plasmin inhibitor. The company plans to present nine studies at the ISTH 2026 Congress, showcasing its commitment to addressing critical gaps in coagulation disorder treatments. Sutacimig has also received FDA Breakthrough Therapy designation, with a Phase 3 trial expected to begin in the second half of 2026.
Read more →COAGHemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Hemab Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference, where its management team will present and hold investor meetings. The event is scheduled for June 4, 2026, in New York, NY. Hemab is focused on developing therapies for blood coagulation disorders, including treatments for Glanzmann thrombasthenia and Von Willebrand Disease.
Read more →COAGHemab Therapeutics Reports First Quarter 2026 Financial Results Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for s
Hemab Therapeutics has reported its first quarter financial results for 2026, highlighting the successful completion of an initial public offering that raised $346.7 million and secured a listing on Nasdaq. The company received Breakthrough Therapy Designation for sutacimig, a bispecific antibody for Glanzmann thrombasthenia. Despite these advancements, Hemab reported a net loss of $22.687 million in the quarter, with a decrease in cash reserves compared to the previous quarter.
Read more →COAGHemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Hemab Therapeutics Holdings, Inc. has successfully closed its upsized initial public offering, selling 19,262,500 shares at $18.00 each. The offering generated approximately $346.7 million in gross proceeds. The company's stock began trading on the Nasdaq Global Select Market under the ticker COAG. The underwriters fully exercised their option to purchase additional shares.
Read more →COAGHemab Therapeutics Announces Pricing of Upsized Initial Public Offering
Hemab Therapeutics Holdings, Inc. has announced the pricing of its initial public offering, offering 16,750,000 shares at $18.00 each. The IPO is expected to generate around $301.5 million in gross proceeds. Trading is set to begin on the Nasdaq Global Select Market under the ticker 'COAG' on May 1, 2026, with the offering closing around May 4, 2026.
Read more →About Hemab Therapeutics Holdings, Inc.
Headquarters101 MAIN STREET, CAMBRIDGE, MA, 02142
Founded2020
BIOPHARMAWATCH ELITE PLUS
Trade the next COAG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime